{"id":3408,"date":"2022-05-24T12:06:04","date_gmt":"2022-05-24T11:06:04","guid":{"rendered":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/?p=3408"},"modified":"2022-05-24T13:58:48","modified_gmt":"2022-05-24T12:58:48","slug":"la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela","status":"publish","type":"post","link":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/","title":{"rendered":"La Unitat de Malaltia de Motoneurona de l\u2019HUB participa en 6 assajos cl\u00ednics sobre l\u2019ELA"},"content":{"rendered":"<p>Us resumim breument les caracter\u00edstiques del 6 assajos en qu\u00e8 participa l\u2019Hospital de Bellvitge. Podeu ampliar la informaci\u00f3 sobre tots ells posant-vos en contacte amb la UFMM de l\u2019HUB: <a href=\"mailto:aulaelapacient@bellvitgehospital.cat\">aulaelapacient@bellvitgehospital.cat<\/a><\/p>\n<p><img loading=\"lazy\" class=\"alignnone wp-image-3415\" src=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-content\/uploads\/sites\/2\/2022\/05\/test-gbc1280209_1280.jpg\" alt=\"\" width=\"518\" height=\"343\" \/><\/p>\n<p><strong>ADORE<\/strong><\/p>\n<p>Avalua una formulaci\u00f3 oral d&#8217;edaravone, un compost que prev\u00e9 l&#8217;estr\u00e8s oxidatiu a les c\u00e8l\u00b7lules. En reduir l&#8217;estr\u00e8s oxidatiu, s\u2019avalua si es pot retardar la progressi\u00f3 de l&#8217;ELA.\u00a0<a href=\"https:\/\/www.ferrer.com\/ca\/ensayo-cl%C3%ADnico-adore\">M\u00e9s informaci\u00f3 sobre l\u2019ADORE.<\/a><\/p>\n<p><a href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-content\/uploads\/sites\/2\/2022\/05\/INCLUSI\u00d3N-EXCLUSI\u00d3N-RESUMIDOS-ADORE.pdf\">Vegeu els criteris d&#8217;inclusi\u00f3\/exclusi\u00f3 de l&#8217;assaig<\/a><\/p>\n<p>Fitxa b\u00e0sica<\/p>\n<ul>\n<li>Mol\u00e8cula en estudi: Edaravone<\/li>\n<li>Formulaci\u00f3: Oral<\/li>\n<li>Promotor: Laboratoris Ferrer\/ TRICALS<\/li>\n<li>Tipus d\u2019assaig: Fase 3<\/li>\n<li>Durada: 48 setmanes<\/li>\n<li>R\u00e0tio de tractament: 2:1<\/li>\n<\/ul>\n<p><strong>PHOENIX<\/strong><\/p>\n<p><strong>\u00a0<\/strong>Es tracta d\u2019un assaig de fase 3, aleatoritzat, controlat amb placebo a m\u00e9s de 70 centres dels Estats Units i Europa per avaluar la seguretat i efic\u00e0cia d&#8217;AMX0035 (fenilbutirat de sodi\/taurursodiol) en pacients d\u2019ELA. <a href=\"https:\/\/www.amylyx.com\/phoenix\">M\u00e9s informaci\u00f3 sobre Phoenix<\/a><\/p>\n<p><a href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-content\/uploads\/sites\/2\/2022\/05\/INCLUSI\u00d3N-EXCLUSI\u00d3N-RESUMIDOS-PHOENIX.pdf\">Vegeu els criteris d&#8217;inclusi\u00f3\/exclusi\u00f3 en l&#8217;assaig<\/a><\/p>\n<ul>\n<li>Mol\u00e8cula en estudi: AMX035<\/li>\n<li>Formulaci\u00f3: Oral<\/li>\n<li>Promotor: Amylyx pharmaceutycals Inc.<\/li>\n<li>Tipus d\u2019assaig: Fase 3<\/li>\n<li>Durada: 48 setmanes<\/li>\n<li>R\u00e0tio de tractament: 3:2<\/li>\n<\/ul>\n<p><strong>COURAGE-ALS<\/strong><\/p>\n<p><strong>\u00a0<\/strong>L\u2019assaig investiga l\u2019efic\u00e0cia y seguridad del f\u00e1rmaco &#8216;reldesemtiv&#8217; para el tratamiento de la ELA.<a href=\"https:\/\/www.tricals.org\/en\/trials\/courage-als-trial\/\"> M\u00e9s informaci\u00f3 sobre l\u2019assaig COURAGE-ALS<\/a><\/p>\n<p><a href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-content\/uploads\/sites\/2\/2022\/05\/Inclusi\u00f3n-Exclusi\u00f3n-Reldesemtiv.pdf\">Vegeu els criteris d&#8217;inclusi\u00f3\/exclusi\u00f3 a l&#8217;assaig<\/a><\/p>\n<ul>\n<li>Mol\u00e8cula en estudi: Reldesemtiv<\/li>\n<li>Formulaci\u00f3: Oral<\/li>\n<li>Promotor:\u00a0Cytokinetics<\/li>\n<li>Tipus d\u2019assaig: Fase 3<\/li>\n<li>Durada: 48 setmanes (En el bra\u00e7 de placebo a las 24 setmanes se passa a Reldesemtiv)<\/li>\n<li>R\u00e0tio de tractament: 2:1<\/li>\n<\/ul>\n<p><strong>AB19001<\/strong><\/p>\n<p><strong>\u00a0<\/strong>Es tracta d\u2019un assaig de fase 3 internacional, multic\u00e8ntric, aleatoritzat, doble cec, controlat amb placebo, de 3 grups paral\u00b7lels per comparar l&#8217;efic\u00e0cia i la seguretat de masitinib en combinaci\u00f3 amb riluzol davant de placebo en combinaci\u00f3 amb riluzol. <a href=\"https:\/\/www.ab-science.com\/ab-science-received-authorization-from-the-fda-to-resume-patient-enrollment-in-the-confirmatory-phase-3-study-of-masitinib-ab19001-in-patients-with-als\/\">M\u00e9s informaci\u00f3 sobre l\u2019assaig AB19001<\/a><\/p>\n<p><a href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-content\/uploads\/sites\/2\/2022\/05\/Inclusi\u00f3n_y_exclusi\u00f3n_resumido-_Masitinib.pdf\">Vegeu els criteris d&#8217;inclusi\u00f3\/exclusi\u00f3 en l&#8217;assaig<\/a><\/p>\n<ul>\n<li>Mol\u00e8cula en estudi: Masitinib<\/li>\n<li>Formulaci\u00f3: Oral<\/li>\n<li>Promotor:\u00a0AB Science<\/li>\n<li>Tipus d\u2019assaig: Fase 3<\/li>\n<li>Durada: 48 setmanes<\/li>\n<li>R\u00e0tio de tractament: 1:1:1 (Masitinib 6mg\/Kg; Masitinib 4.5mg\/Kg; Placebo)<\/li>\n<\/ul>\n<p><strong>MERIDIAN<\/strong><em> (Reclutament tancat)<\/em><\/p>\n<p>\u00c9s un assaig cl\u00ednic de fase 2 que avalua l&#8217;efic\u00e0cia i la seguretat del medicament en investigaci\u00f3, pegcetacoplan, en adults amb ELA no heredit\u00e0ria. <a href=\"https:\/\/www.meridiantrial.com\/\">M\u00e9s informaci\u00f3 sobre l\u2019assaig Meridian<\/a><\/p>\n<p><a href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-content\/uploads\/sites\/2\/2022\/05\/Criterios-inclusio-exclusion-MERIDIAN-resumido.pdf\">Vegeu els criteris d&#8217;inclusi\u00f3\/exclusi\u00f3 de l&#8217;assaig<\/a><\/p>\n<ul>\n<li>Mol\u00e8cula en estudi: Pegcetacoplan<\/li>\n<li>Formulaci\u00f3: Subcut\u00e0nia<\/li>\n<li>Promotor:\u00a0Apellis<\/li>\n<li>Tipus d\u2019assaig: Fase 2<\/li>\n<li>Durada: 52 setmanes<\/li>\n<li>R\u00e0tio de tractament: 1:1<\/li>\n<\/ul>\n<p><strong>BASICHR0053<\/strong><\/p>\n<p>El prop\u00f2sit d\u2019aquest assaig \u00e9s avaluar la viabilitat, l\u2019acceptaci\u00f3 per part del pacient, l\u2018adher\u00e8ncia i la validesa de la recopilaci\u00f3 de par\u00e0metres digitals a la llar que s\u00f3n rellevants per a l\u2019avaluaci\u00f3 de la malaltia en pacients d\u2019ELA. L&#8217;objectiu \u00e9s determinar quins d\u2019aquests par\u00e0metres s\u00f3n predictors fiables de l\u2019evoluci\u00f3 de la malaltia.<\/p>\n<p><a href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-content\/uploads\/sites\/2\/2022\/05\/INCLUSI\u00d3N-DE-CRITERIOS-BASICHR0053.pdf\">Vegeu els criteris d&#8217;inclusi\u00f3\/exclusi\u00f3 de l&#8217;assaig<\/a><\/p>\n<ul>\n<li>Mol\u00e8cula en estudi: Cap.<\/li>\n<li>Formulaci\u00f3: Valoraci\u00f3 de dispositius de control.<\/li>\n<li>Promotor:\u00a0Novartis<\/li>\n<li>Tipus d\u2019assaig: Valoraci\u00f3 de dispositius de control.<\/li>\n<li>Durada: 270 dies<\/li>\n<li>R\u00e0tio de tractament: &#8211;<\/li>\n<\/ul>\n<div class=\"sharedaddy sd-sharing-enabled\"><div class=\"robots-nocontent sd-block sd-social sd-social-icon sd-sharing\"><h3 class=\"sd-title\">Comparteix aix\u00f2:<\/h3><div class=\"sd-content\"><ul><li class=\"share-facebook\"><a rel=\"nofollow\" data-shared=\"sharing-facebook-3408\" class=\"share-facebook sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/?share=facebook\" target=\"_blank\" title=\"Comparteix al Facebook\"><span><\/span><span class=\"sharing-screen-reader-text\">Comparteix al Facebook (Opens in new window)<\/span><\/a><\/li><li class=\"share-twitter\"><a rel=\"nofollow\" data-shared=\"sharing-twitter-3408\" class=\"share-twitter sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/?share=twitter\" target=\"_blank\" title=\"Feu clic per compartir al Twitter\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per compartir al Twitter (Opens in new window)<\/span><\/a><\/li><li class=\"share-google-plus-1\"><a rel=\"nofollow\" data-shared=\"sharing-google-3408\" class=\"share-google-plus-1 sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/?share=google-plus-1\" target=\"_blank\" title=\"Feu clic per compartir a Google+\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per compartir a Google+ (Opens in new window)<\/span><\/a><\/li><li class=\"share-email\"><a rel=\"nofollow\" data-shared=\"\" class=\"share-email sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/?share=email\" target=\"_blank\" title=\"Feu clic per enviar un correu electr\u00f2nic a un amic\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per enviar un correu electr\u00f2nic a un amic (Opens in new window)<\/span><\/a><\/li><li class=\"share-print\"><a rel=\"nofollow\" data-shared=\"\" class=\"share-print sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/\" target=\"_blank\" title=\"Feu clic per imprimir\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per imprimir (Opens in new window)<\/span><\/a><\/li><li class=\"share-end\"><\/li><\/ul><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Us resumim breument les caracter\u00edstiques del 6 assajos en qu\u00e8 participa l\u2019Hospital de Bellvitge. Podeu ampliar la informaci\u00f3 sobre tots ells posant-vos en contacte amb la UFMM de l\u2019HUB: aulaelapacient@bellvitgehospital.cat ADORE Avalua una formulaci\u00f3 oral d&#8217;edaravone, un compost que prev\u00e9 &hellip; <a href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/\">Continua llegint <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n<div class=\"sharedaddy sd-sharing-enabled\"><div class=\"robots-nocontent sd-block sd-social sd-social-icon sd-sharing\"><h3 class=\"sd-title\">Comparteix aix\u00f2:<\/h3><div class=\"sd-content\"><ul><li class=\"share-facebook\"><a rel=\"nofollow\" data-shared=\"sharing-facebook-3408\" class=\"share-facebook sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/?share=facebook\" target=\"_blank\" title=\"Comparteix al Facebook\"><span><\/span><span class=\"sharing-screen-reader-text\">Comparteix al Facebook (Opens in new window)<\/span><\/a><\/li><li class=\"share-twitter\"><a rel=\"nofollow\" data-shared=\"sharing-twitter-3408\" class=\"share-twitter sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/?share=twitter\" target=\"_blank\" title=\"Feu clic per compartir al Twitter\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per compartir al Twitter (Opens in new window)<\/span><\/a><\/li><li class=\"share-google-plus-1\"><a rel=\"nofollow\" data-shared=\"sharing-google-3408\" class=\"share-google-plus-1 sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/?share=google-plus-1\" target=\"_blank\" title=\"Feu clic per compartir a Google+\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per compartir a Google+ (Opens in new window)<\/span><\/a><\/li><li class=\"share-email\"><a rel=\"nofollow\" data-shared=\"\" class=\"share-email sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/?share=email\" target=\"_blank\" title=\"Feu clic per enviar un correu electr\u00f2nic a un amic\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per enviar un correu electr\u00f2nic a un amic (Opens in new window)<\/span><\/a><\/li><li class=\"share-print\"><a rel=\"nofollow\" data-shared=\"\" class=\"share-print sd-button share-icon no-text\" href=\"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/la-unitat-de-malaltia-de-motoneurona-de-lhub-participa-en-6-assajos-clinics-sobre-lela\/\" target=\"_blank\" title=\"Feu clic per imprimir\"><span><\/span><span class=\"sharing-screen-reader-text\">Feu clic per imprimir (Opens in new window)<\/span><\/a><\/li><li class=\"share-end\"><\/li><\/ul><\/div><\/div><\/div>","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[1415,1423,1409,1419,1421,235,204,1417,1411,1187,1413],"_links":{"self":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/posts\/3408"}],"collection":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/comments?post=3408"}],"version-history":[{"count":3,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/posts\/3408\/revisions"}],"predecessor-version":[{"id":3420,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/posts\/3408\/revisions\/3420"}],"wp:attachment":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/media?parent=3408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/categories?post=3408"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/aulaela\/wp-json\/wp\/v2\/tags?post=3408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}